Neurocrine Biosciences presents data on the demographic and clinical characteristics of pediatric patients with SCN8A-related epilepsy at AES 2022
SAN DIEGO, December 2, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today released demographic and clinical data from studies based on genetic screening of children with SCN8A– related epilepsies. Data was collected from over 17,000 patients through Invitee Corporation’s Behind the Seizure® Program, of which Neurocrine Biosciences is a …